Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 186

    1.

    Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.

    Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O.

    J Viral Hepat. 2012 Feb;19(2):e97-104. doi: 10.1111/j.1365-2893.2011.01512.x. Epub 2011 Oct 4.

    PMID:
    22239532
    [PubMed - indexed for MEDLINE]
    2.

    Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation.

    Grover VP, Pavese N, Koh SB, Wylezinska M, Saxby BK, Gerhard A, Forton DM, Brooks DJ, Thomas HC, Taylor-Robinson SD.

    J Viral Hepat. 2012 Feb;19(2):e89-96. doi: 10.1111/j.1365-2893.2011.01510.x. Epub 2011 Oct 17.

    PMID:
    22239531
    [PubMed - indexed for MEDLINE]
    3.

    Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.

    Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R.

    J Viral Hepat. 2012 Feb;19(2):e81-8. doi: 10.1111/j.1365-2893.2011.01507.x. Epub 2011 Aug 16.

    PMID:
    22239530
    [PubMed - indexed for MEDLINE]
    4.

    Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication.

    Rance E, Tanner JE, Alfieri C.

    J Viral Hepat. 2012 Feb;19(2):e73-80. doi: 10.1111/j.1365-2893.2011.01505.x. Epub 2011 Aug 16.

    PMID:
    22239529
    [PubMed - indexed for MEDLINE]
    5.

    Tumour necrosis factor-α-857T allele reduces the risk of hepatitis B virus infection in an Asian population.

    Shi KQ, Cai XH, Xiao DD, Wu SJ, Peng MM, Lin XF, Liu WY, Fan YC, Chen YP, Zheng MH.

    J Viral Hepat. 2012 Feb;19(2):e66-72. doi: 10.1111/j.1365-2893.2011.01540.x. Epub 2011 Nov 17.

    PMID:
    22239528
    [PubMed - indexed for MEDLINE]
    6.

    Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection.

    Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S, Kronenberger B, Piiper A.

    J Viral Hepat. 2012 Feb;19(2):e58-65. doi: 10.1111/j.1365-2893.2011.01536.x. Epub 2011 Oct 17.

    PMID:
    22239527
    [PubMed - indexed for MEDLINE]
    7.

    Impact of hepatitis B virus infection on metabolic profiles and modifying factors.

    Hsu CS, Liu CH, Wang CC, Tseng TC, Liu CJ, Chen CL, Chen PJ, Chen DS, Kao JH.

    J Viral Hepat. 2012 Feb;19(2):e48-57. doi: 10.1111/j.1365-2893.2011.01535.x. Epub 2011 Sep 29.

    PMID:
    22239526
    [PubMed - indexed for MEDLINE]
    8.

    Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B.

    Kwon JH, Jang JW, Lee S, Lee J, Chung KW, Lee YS, Choi JY.

    J Viral Hepat. 2012 Feb;19(2):e41-7. doi: 10.1111/j.1365-2893.2011.01509.x. Epub 2011 Nov 20.

    PMID:
    22239525
    [PubMed - indexed for MEDLINE]
    9.

    Comparison of the hepatitis B virus core, surface and polymerase gene substitution rates in chronically infected patients.

    van de Klundert MA, Cremer J, Kootstra NA, Boot HJ, Zaaijer HL.

    J Viral Hepat. 2012 Feb;19(2):e34-40. doi: 10.1111/j.1365-2893.2011.01506.x. Epub 2011 Aug 16.

    PMID:
    22239524
    [PubMed - indexed for MEDLINE]
    10.

    Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells.

    Shi CC, Tjwa ET, Biesta PJ, Boonstra A, Xie Q, Janssen HL, Woltman AM.

    J Viral Hepat. 2012 Feb;19(2):e26-33. doi: 10.1111/j.1365-2893.2011.01496.x. Epub 2011 Aug 31.

    PMID:
    22239523
    [PubMed - indexed for MEDLINE]
    11.

    Ischaemic colitis during interferon treatment for chronic hepatitis C: report of two cases and literature review.

    Kawaguchi T, Ide T, Itou M, Suetsugu M, Yoshioka S, Sakata M, Taniguchi E, Oriishi T, Sumie S, Tsuruta O, Sata M.

    J Viral Hepat. 2012 Feb;19(2):e220-4. doi: 10.1111/j.1365-2893.2011.01501.x. Epub 2011 Aug 4. Review.

    PMID:
    22239522
    [PubMed - indexed for MEDLINE]
    12.

    Predictors of outcome in children with acute viral hepatitis and coagulopathy.

    Srivastava A, Yachha SK, Poddar U.

    J Viral Hepat. 2012 Feb;19(2):e194-201. doi: 10.1111/j.1365-2893.2011.01495.x. Epub 2011 Aug 4.

    PMID:
    22239519
    [PubMed - indexed for MEDLINE]
    13.

    Immunohistochemistry for the diagnosis of hepatitis E virus infection.

    Gupta P, Jagya N, Pabhu SB, Durgapal H, Acharya SK, Panda SK.

    J Viral Hepat. 2012 Feb;19(2):e177-83. doi: 10.1111/j.1365-2893.2011.01498.x. Epub 2011 Oct 7.

    PMID:
    22239516
    [PubMed - indexed for MEDLINE]
    14.

    Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus.

    Sebastiani G, Tempesta D, Alberti A.

    J Viral Hepat. 2012 Feb;19(2):e170-6. doi: 10.1111/j.1365-2893.2011.01508.x. Epub 2011 Sep 14.

    PMID:
    22239515
    [PubMed - indexed for MEDLINE]
    15.

    Examining hepatitis C virus testing practices in primary care clinics.

    Almario CV, Vega M, Trooskin SB, Navarro VJ.

    J Viral Hepat. 2012 Feb;19(2):e163-9. doi: 10.1111/j.1365-2893.2011.01539.x. Epub 2011 Nov 17.

    PMID:
    22239514
    [PubMed - indexed for MEDLINE]
    16.

    Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C.

    Cheng JC, Yeh YJ, Huang YH, Liang KH, Chang ML, Lin CY, Yeh CT.

    J Viral Hepat. 2012 Feb;19(2):e154-62. doi: 10.1111/j.1365-2893.2011.01538.x. Epub 2011 Oct 7.

    PMID:
    22239513
    [PubMed - indexed for MEDLINE]
    17.

    Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry.

    Calès P, Zarski JP, Marc Chapplain J, Bertrais S, Sturm N, Michelet C, Babany G, Chaigneau J, Eddine Charaf M; multicentric groups (Fibrosys, ANRS HC 12, Fibrostop).

    J Viral Hepat. 2012 Feb;19(2):e143-53. doi: 10.1111/j.1365-2893.2011.01531.x. Epub 2011 Oct 30.

    PMID:
    22239512
    [PubMed - indexed for MEDLINE]
    18.

    Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.

    Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H.

    J Viral Hepat. 2012 Feb;19(2):e134-42. doi: 10.1111/j.1365-2893.2011.01528.x. Epub 2011 Nov 8.

    PMID:
    22239511
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.

    Miki D, Ohishi W, Ochi H, Hayes CN, Abe H, Tsuge M, Imamura M, Kamatani N, Nakamura Y, Chayama K.

    J Viral Hepat. 2012 Feb;19(2):e126-33. doi: 10.1111/j.1365-2893.2011.01516.x. Epub 2011 Sep 14.

    PMID:
    22239510
    [PubMed - indexed for MEDLINE]
    20.

    Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.

    Craxi A, Koutsounas S, Ogurtsov P, Chemello L, Maticic M, Torras J, Diago M, Tartaglione MT, Witthoeft T, Yu X, Faruqi R, Chaudhri E, Pedicone LD, Zuckerman E.

    J Viral Hepat. 2012 Feb;19(2):e120-5. doi: 10.1111/j.1365-2893.2011.01515.x. Epub 2011 Sep 19.

    PMID:
    22239509
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk